Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 17Lymphoid 17Plasma cell 11Myeloid 7Other 6Head & Neck 5Sarcoma 2Thoracic 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Stomatitis 1Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibroblast Growth Factor 7 × Gastrointestinal × Clear all
NCT00393822 2014-07-15

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

Amgen

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡